Positive Asian Results Set Stage For Japan Perampanel Filing
This article was originally published in PharmAsia News
Eisai has unveiled additional positive results for its novel anti-epileptic drug perampanel, this time from an Asian trial in refractory patients that will be used to support a planned Japanese approval filing.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.